CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma
Authors:
- Kenichi NishimuraKNKenichi Nishimura
- Tatsuya KonishiTKTatsuya Konishi
- Toshiki OchiTOToshiki Ochi
- Ryuta WatanabeRWRyuta Watanabe
- Terutaka NodaTNTerutaka Noda
- Tetsuya FukumotoTFTetsuya Fukumoto
- Noriyoshi MiuraNMNoriyoshi Miura
- Yuki MiyauchiYMYuki Miyauchi
- Tadahiko KikugawaTKTadahiko Kikugawa
- Katsuto TakenakaKTKatsuto Takenaka
- Takashi SaikaTSTakashi Saika
Open Access
- 28 May 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (6) , 888
Abstract
Immune checkpoint inhibitor (ICI) therapy increases the risk of immune-related adverse events (irAEs). In particular, combination checkpoint blockade (CCB) targeting inhibitory CTLA-4 and PD-1 receptors could lead to irAEs at a higher rate than ICI monotherapy. Management of irAEs is important while using ICIs. However, there are no reliable biomarkers for predicting irAEs. The aim of this study was to elucidate early B cell changes after CCB therapy in patients with renal cell carcinoma (RCC) and verify whether B cells can be a predictor of irAEs. This prospective cohort study was conducted with 23 Japanese patients with metastatic RCC. An increase in the proportion of CD21lo B cells and CD21lo memory B cells was confirmed following CCB therapy. Although there were no differences in clinical outcomes between irAE and no-irAE groups, the proportion of CD21lo B cells at baseline was lower in the irAE group, with a significant increase after the first cycle of CCB therapy. Further analysis revealed a moderate correlation between irAEs and CD21lo B cell levels at baseline (area under the curve: 0.83, cut-off: 3.13%, sensitivity: 92.3, specificity: 70.0). This finding indicates that patients with low baseline CD21lo B cell levels warrant closer monitoring for irAEs. The clinical registration number by the Certified Review Board of Ehime University is No. 1902011.Keywords
This publication has 20 references indexed in Scilit:
- The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanomaCancer Medicine, 2016
- CD21–/low B cells in human blood are memory cellsClinical and Experimental Immunology, 2016
- Anergic B Cells: Precarious On-Call Warriors at the Nexus of Autoimmunity and False-Flagged PathogensFrontiers in Immunology, 2015
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Microbial colonization influences early B-lineage development in the gut lamina propriaNature, 2013
- Complement receptor 2/CD21− human naive B cells contain mostly autoreactive unresponsive clonesBlood, 2010
- Multiple paths to loss of anergy and gain of autoimmunityAutoimmunity, 2007
- Role of LAG-3 in Regulatory T CellsImmunity, 2004
- Th1 and Th2 CD4+ T Cells Provide Help for B Cell Clonal Expansion and Antibody Synthesis in a Similar Manner In VivoThe Journal of Immunology, 2000
- LAG-3, a novel lymphocyte activation gene closely related to CD4.Journal of Experimental Medicine, 1990